Src homology 2 (SH2) domain-mediated interactions with phosphotyrosine residues are critical in many intracellular signal transduction pathways. Attempts to understand the determinants of specificity and selectivity of these interactions have prompted many binding studies that have used several techniques. Some discrepancies, in both the absolute and relative values of the dissociation constants for particular interactions, are apparent. To establish the correct dissociation constants and to understand the origin of these differences, we have analyzed three previously determined interactions using the techniques of surface plasmon resonance and isothermal titration calorimetry. We find that the binding of SH2 domains to phosphopeptides is weaker than generally presumed. A phosphopeptide based on the hamster polyoma middle tumor antigen interacts with the SH2 domain from Src with an equilibrium dissociation constant (Kd) of 600 nM; a phosphopeptide based on one binding site from the platelet-derived growth factor receptor binds to the Nterminal SH2 domain of the 1-phosphatidylinositol 3-kinase p85 subunit with a Kd of 300 nM; and a phosphopeptide based on the C terminus of Lck binds to the SH2 domain of Lck with a Kd of 4 ,uM. In addition, we demonstrate that avidity effects that result from the dimerization of glutathione S-transferase fusion proteins with SH2 domains could be responsible for overestimates of affinities for these interactions previously studied by surface plasmon resonance.
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The specificity of signaling pathways involving tyrosine kinases is thought to be defined, at least in part, by Src homology 2 (SH2) domain-mediated interactions. SH2 domains interact with tyrosine residues that have been phosphorylated by kinases in the pathway (1, 2) . Mutagenesis studies have shown that particular phosphotyrosine [Tyr(P)] residues in activated receptors serve to recruit particular downstream signaling molecules via interactions with their SH2 domains (3) (4) (5) . This indicates that the specificity of these SH2-Tyr(P) interactions in intracellular signaling pathways is defined by the sequence and structural context of the Tyr(P) residue. These interactions can be reconstituted by using short peptides that contain a Tyr(P) residue (6) . Studies involving selection from randomized Tyr(P)-containing peptide libraries have shown that specific motifs, based on the amino acids proximal to the Tyr(P) residue, are recognized by different SH2 domains (7) . Through use of such peptides in several techniques, relative affinities have been reported for various SH2-peptide interactions. Kd values from 10 ,uM to 0.1 nM have been reported, representing a wide range over which specificity can apply. There are, however, a number of discrepancies in the reported data.
The Kd for the interaction between the SH2 domain of Src [in the form of a fusion protein with glutathione S-transferase (GST)] and a peptide based on the tyrosine phosphorylation site
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. from hamster polyoma middle tumor (hmT) antigen, for example, has variously been determined by surface plasmon resonance (SPR) to be in the range of 3.5 nM (8) to 80 nM (9) . This reaction is supposedly one of the highest affinity SH2-phosphopeptide interactions (7) , and the crystal structure of the complex indicates that interface between the molecules is intimate (10) .
The N-terminal SH2 domain from the p85 subunit of I-phosphatidylinositol 3-kinase selected the motifs Tyr(P)-Val-Xaa-Met and Tyr(P)-Met-Xaa-Met from peptide libraries with randomized sequences C-terminal to the Tyr(P) residue (7) . The interaction of this SH2 domain with phosphopeptides containing these motifs has been studied previously, but the reported affinities are inconsistent (11) (12) (13) .
In a previous study by isothermal titration calorimetry (ITC), the interaction of the SH2 domain from Lck (Lck SH2) with a peptide based on its autoregulatory Tyr(P)-containing C terminus [Tyr(P)-505] gave an equilibrium dissociation constant of 3 ,uM (14) . This value is significantly lower than that reported for other such reactions. A number of studies indicate that this is a physiologically relevant interaction with defined specificity (15) (16) (17) (18) . Furthermore, structural studies illustrate an intimate interface between this peptide and the Lck SH2 domain (19) . By contrast with the apparently weak interaction suggested by these ITC studies, a Kd value of -25 nM for the same interaction can be estimated from a combination of SPR and displacement studies (8) . The fact that there is disagreement by some 2 orders of magnitude between these two studies prompted us to determine the true dissociation constant and the origin of the very high reported affinities. The primary difference between the studies is in the techniques used (ITC and SPR). Furthermore, while the ITC studies employed the isolated Lck SH2 domain, those with SPR employed Lck SH2 in the form of a fusion protein with GST.
In this work we use both ITC and SPR methods to investigate the interactions of both free and GST-fusion SH2 domains. We have concentrated on three previously reported SH2 domainphosphopeptide interactions: those of Src with the hmT Tyr(P)-315, p85 with the platelet-derived growth factor receptor (PDGFR) Tyr(P)-751, and Lck with the Lck Tyr(P)-505 phosphopeptides. The ITC studies suggest that fusion of the SH2 domain to GST does not affect its affinity for tyrosyl phosphopeptides. However, since GST-fusion proteins dimerize (13) (human c-Src amino acids 147-252) and Lck (human c-Lck amino acids 123-228) were purified both as fusions with GST and as free SH2 domains. The GST-conjugated Lck SH2, GST-conjugated Src SH2, and Src SH2 polypeptides were purified as described (8) . Expression of the Lck SH2 (residues 123-228) and the N-terminal p85 SH2 (residues 321-440) from pETlla was directed by the T7 promoter (20) , and the SH2 domains were purified as described (14) . The final GST-Src SH2, GST-Lck SH2, Src SH2, Lck SH2, and p85 SH2 samples were >98% pure as judged by SDS/PAGE. [NH>-Thr.-Ala-Thr-Glu-Gly-Gln-Tyr(P)-Gln-Pro-Gly-Pro-COO-]. Peptides were synthesized as described (12, 14, 
21).
Peptides were characterized by fast atom bombardment mass spectrometry, analytical HPLC, and NMR and were determined as being >95% pure. Concentrations of peptides were determined by weight and amino acid analysis.
SPR Analysis. The phenomenon of SPR and its application in determination of real-time binding events have been described (22, 23 (14, 26, 27) .
ITC studies were performed with the Omega instrument (MicroCal, Amherst, MA). All experiments were performed at 25°C in MBS. Titration curves were fit by using the ORIGIN program supplied by the manufacturers (26, 27) . For all experiments, the heats of dilution for the individual reactants were determined by the titration of peptide into buffer (from dialysis of SH2 domain; ref. 14) and buffer into the SH2 domain. The sum of these heats was subtracted from the raw titration data prior to fitting. In all experiments the c value (c = Kb-[SH2 domain]; ref. 26 ) was in a range that provided data suitable for the accurate determination of binding constants (c ranged from 107 to 2.5).
RESULTS AND DISCUSSION
Motivated by the discrepancies between our previous SPR and ITC studies and those reported by others, we attempted to reassess the affinities of phosphopeptides for SH2 domains. We focused on three interactions: (i) the Src SH2-hmT phosphopeptide interaction, where significant differences between values obtained by SPR analysis have been reported (8, 9) ; (ii) the p85 N-terminal SH2-PDGFR Tyr(P)-751 phosphopeptide interaction, which is a specific physiological interaction and has been studied by competition assays and SPR (11) (12) (13) ; and (iii) the Lck SH2-Tyr(P)-505 phosphopeptide interaction, where there exists a difference of 2 orders of magnitude between the Kd determined from ITC studies (14) and that inferred from SPR studies (8) .
Interaction of Free SH2 Domains with Phosphopeptides. We initially determined Kd values for interaction of phosphopeptides with free SH2 domains in each of the cases described above, using SPR or ITC or both. (14) . These Kd values indicate that the affinity of these SH2 domains for their specific phosphopeptides is lower by as much as 2 orders of magnitude than previously reported (Table 1) .
A typical SPR sensorgram is shown in Fig. 1 (27) . Similarly small entropic contributions to the binding of phosphopeptides to SH2 domains have been observed in previous studies (14) .
The interaction of the Lck SH2 domain with the phosphopeptide based on the C terminus of Lck [Tyr(P)-505 peptide] could not be determined accurately using SPR. This interaction is significantly weaker than the others studied here, and the resulting sensorgrams were poorly defined. Indeed, it should be noted that Kd values associated with the interactions studied here fall into the ideal range of Kd values for study by ITC (100 ,tM to 10 nM) but are at the high end of those for determination by SPR. The reduced affinity of the Lck SH2-Tyr(P)-505 interaction may reflect the fact that, in vivo, interaction of Lck SH2 with the phosphorylated Lck C terminus appears to be intramolecular. The local concentration of the Tyr(P)-505 region that is experienced by the SH2 domain will therefore be greatly increased.
The Src-hmT Tyr(P)-315 and N-p85-PDGFR Tyr(P)-751 interactions correspond to interactions that were selected for from peptide libraries with randomized amino acids C-terminal to the Tyr(P) residue (7). These interactions have similar affinities (Table 1) . Interestingly, the Tyr(P)-505 peptide was not selected for by Src-family SH2 domains (which include Lck) despite its binding to these domains being just 1 order of magnitude weaker. The Tyr(P)-Glu-Glu-Ile (hmT) peptide that was selected by Src-family SH2 domains in these studies binds to Lck SH2 with an affinity similar to that measured for the Src SH2-hmT phosphopeptide interaction (data not shown).
The affinities we obtain for all the interactions studied here are substantially weaker than values reported in the literature. This strongly suggests a systematic difference between present studies and those presented elsewhere. The most obvious difference between our affinity measurements and those of others is that the studies described here used free SH2 domains, whereas GST-SH2 fusion proteins were used in previous work.
Interaction of GST-SH2 Domains with Phosphopeptides. GST and fusion proteins formed by covalent link to GST are known to dimerize in solution (13, 28) . Except for effects on the conformation of the fused SH2 domain, the presence of the GST should not influence the affinity of the SH2 domain for phosphopeptides free in solution. In ITC studies the interacting species are both in solution, so we would expect GST-SH2 fusion proteins to give the same affinity for phosphopeptides as do free SH2 domains. This indeed was observed with both the Src SH2 and the Lck SH2 domains, as no significant differences could be detected between titrations of phos- phopeptides into solutions of free SH2 domain and of the GST-SH2 fusion protein (Table 1 ). These data confirm that fusion of the SH2 domains to GST does not influence their binding to phosphopeptides.
SPR studies, by contrast, involve the binding of the SH2 domain or the GST-SH2 fusion protein to a surface on which phosphopeptides have been immobilized. The property that is measured is actually the affinity of the SH2 (or GST-SH2) domain for this surface. Under these circumstances, dimerization of the GST-SH2 fusion protein presents a number of potential problems. If phosphopeptides are closely spaced on the hydrogel, the dimeric GST-SH2 fusion protein may bind simultaneously to two phosphopeptides. In this case, the apparent affinity measured by SPR will reflect the combined free energy for two SH2-phosphopeptide interactions and will result in an overestimate of the binding affinity. This divalent attachment can be described as an avidity effect. In addition, since the response signal in SPR is proportional to the mass of material that binds to the hydrogel, the binding of both monomers and dimers to immobilized phosphopeptides would complicate analysis.
To investigate the effects of divalent attachment upon the apparent affinity of SH2-phosphopeptide interactions measured by SPR, we varied the concentration of phosphopeptide on the hydrogel. The amount of peptide bound is monitored by the change in refractive index of the hydrogel compared with the value obtained when no peptide is present (given in arbitrary RU). To obtain data for the GST-Src SH2-hmT phosphopeptide interaction that would fit to a simple bimolecular model, the RU value for peptide bound to the chip had to be <100. This is in contrast to determinations in the absence of the GST fusion, where data could be fit to this model at higher peptide concentrations. These results indicate that, at higher concentrations of peptide on the hydrogel, the GST-SH2 fusion in its dimeric form binds in more than one mode: presumably via bivalent and monovalent interactions. At lower peptide concentrations on the hydrogel, however, binding is predominantly monovalent, minimizing the avidity effect. Reduction of the phosphopeptide concentration on the hydrogel to levels <0.1 ng'mm-2 of chip surface results in a significant loss in the signal-to-noise ratio. However, we find it necessary to work at this lower end of the instrument's detection limits to avoid artifacts associated with binding of dimeric GST-SH2 fusion protein to the hydrogel.
If GST-SH2 fusion proteins exist in both monomeric and dimeric forms, the apparent affinity in SPR studies will also reflect the indiscriminate binding of monomer and dimer to the hydrogel. The relative amounts of monomer and dimer that bind will depend on the equilibrium dimerization constant of the GST-SH2 fusion protein. Changing the concentration of GST-SH2 fusion polypeptide over a range of 10 ALM to 1 nM did not affect the affinities measured in SPR studies. This indicates either that the dimerization constant for GST-SH2 is sufficiently high that all GST-SH2 is present in the dimeric form. This fact must be taken into account in the determination of the Kd. The concentration of active polypeptide in the solution is reduced to half of the total concentration as a result of dimerization, assuming that each dimer binds to a single phosphopeptide on a hydrogel where the phosphopeptide concentration has been reduced to levels where avidity effects are precluded.
As described above, reported affinities are discrepant where GST-SH2 fusion proteins have been employed. The results reported here suggest very strongly that these studies overestimate the apparent affinity as a result of avidity effects. When these avidity effects are negated, ITC and SPR studies agree very well for both free SH2 domains and GST-SH2 fusions (Table 1) .
CONCLUSION
The interaction of SH2 domains with Tyr(P) residues in receptor tyrosine kinases or intracellular signaling proteins plays an important role in determining the specificity of signaling pathways. Through mutational analysis, the Tyr(P) residues that constitute the binding sites for various SH2 domains have been mapped in these molecules, and the roles of the interactions have been studied. The interactions medi-ated by SH2 domains have been reconstituted in vitro through the use of synthetic Tyr(P)-containing peptides. To understand the determinants of specificity and the extent to which synthetic peptides mimic the in vivo SH2-domain ligands, it is important to have a detailed knowledge of the thermodynamics, kinetics, and structural context of complex formation (29) . Several reports in the literature have addressed the binding of SH2 domains to synthetic phosphopeptides, but the measured affinities show significant discrepancies between studies. Indeed, even the affinities reported for a particular interaction can cover a range of up to 2 orders of magnitude.
We have analyzed the binding of three different SH2 domains (isolated or as GST-SH2 fusion proteins) to their cognate phosphopeptides using both SPR and ITC. Our results suggest that SH2-phosphopeptide interactions are significantly weaker than generally supposed. The Kd values that we report are consistent between techniques, and we believe them to represent the true affinities for these interactions. We have investigated one potential source of the discrepancies in previously reported SPR studies. The high affinities that have been quoted are likely to reflect avidity effects in SPR studies that result from dimerization of GST present in a fusion protein with the SH2 domains. When we correct for this effect, we find good agreement in the analyses of a particular SH2-phosphopeptide interaction by both ITC and SPR and complete agreement between studies using both isolated SH2 domains and GST-SH2 fusion proteins.
In vitro studies suggest that the difference between the binding affinities of specific and of nonspecific phosphopeptides to several SH2 domains is relatively small (11, 12, 14) . However, in vivo mutational analysis indicates that, for certain receptors., the difference is likely to be much greater. Indeed, it is possible to prevent completely the binding of an individual SH2 domain-containing signaling protein by elimination of a single tyrosine phosphorylation site. For example, mutation of Tyr-766 in the fibroblast growth factor receptor to phenylalanine prevents the binding of phospholipase C type -y (PLCy) to the receptor and subsequent activation of phosphotidylinositol bisphosphate hydrolysis (5, 30, 31) . Similarly, the binding of individual SH2 domain-containing signaling molecules to PDGFR can be prevented by mutation of individual tyrosine phosphorylation sites (32) (33) (34) . In the case of epidermal growth factor receptor (EGFR), however, the selectivity appears to be less strict. Elimination of the apparent primary binding sites in the C terminus of EGFR for the Grb2 and PLC-y SH2 domains does not completely prevent activation of pathways involving these signaling proteins (35, 36) . A number of other autophosphorylation sites also exist in the C terminus of EGFR, and these may bind the Grb2 and PLC-y SH2 domains in the absence of the primary sites. This suggests that, as seen in vitro, there is less specificity for particular Tyr(P) residues in this case. Thus, while studies utilizing synthetic peptides may mimic the apparent specificity in the EGFR case, in other receptors it appears to be much greater, leading to an all-or-none effect in the mutational analysis. These observations suggest that, in addition to the primary structural context, the tertiary structural environment of the Tyr(P) residue may also play a role in the determination of specificity in SH2 domain-mediated interactions.
